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RadiosensitisationBackground and purpose: In muscle-invasive bladder cancer there is an urgent need to identify relatively
non-toxic radiosensitising agents for use in elderly patients. Histone deacetylase inhibitors radiosensitise
tumour cells but not normal cells in vitro and variously downregulate DNA damage signalling, homolo-
gous recombination (HR) and non-homologous end-joining (NHEJ) repair proteins. We investigated pan-
obinostat (PAN) as a potential radiosensitiser in bladder cancer cells.
Materials and methods: Clonogenic assays were performed in RT112 bladder cancer cells, and RT112 cells
stably knocked down for RAD51 or Ku80 by shRNAi. Resolution of cH2AX foci was determined by immu-
noﬂuorescence confocal microscopy, cell cycle progression by FACS analysis and protein expression by
western blotting.
Results: PAN had a greater radiosensitising effect in Ku80KD than RT112 or RAD51KD cells; enhancement
ratios 1.35 for Ku80KD at 10 nM (IC20 for Ku80KD) and 1.31 for RT112 and RAD51KD at 25 nM (IC40 for
both). PAN downregulated MRE11, NBS1 and RAD51, but not Ku70 and Ku80, increased cH2AX foci for-
mation in a dose-dependent manner and delayed cH2AX foci repair after ionising radiation.
Conclusions: PAN acts as a radiosensitiser in bladder cancer cell lines, and appears to target HR rather
than NHEJ. As muscle-invasive bladder tumours have reduced Ku-DNA binding, PAN could be particularly
useful as a radiosensitiser in bladder cancer.
 2013 Elsevier Ireland Ltd. Published by Elsevier Ireland Ltd.
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Open access under CC BY-NC-ND license.Bladder cancer is the 9th commonest cancer worldwide, with
over 330,000 people diagnosed and over 130,000 dying from the
disease annually [1]. Muscle-invasive bladder cancer can be trea-
ted by neo-adjuvant chemotherapy, followed by either surgical re-
moval of the bladder (cystectomy) or radical radiotherapy (RT)
with or without concurrent chemotherapy (CRT), with similar re-
sults [2]. Older patients tolerate surgery and chemotherapy poorly.
As the overall population ages, we are witnessing increasing num-
bers of patients with bladder cancer who are unable to tolerate
toxic treatments. There is therefore an urgent need to test novel,
less toxic agents in combination with ionising radiation, as poten-
tial clinical radiosensitisers in this disease.
Double strand breaks (DSB) are the lethal DNA lesions caused
by ionising radiation. Cells have two major mechanisms to repairDSB: non-homologous end-joining (NHEJ) and homologous recom-
bination (HR). NHEJ predominates in G1/early S phase but is
error-prone; Ku70, Ku80 and DNA-PK are its key initiators [3].
HR is active in late S/G2 phase, as it requires a sister chromatid
to act as a repair template, and is error free; the MRE11/RAD50/
NBS1 complex and RAD51 are key components [4,5].
Histone deacetylase inhibitors (HDACi) have known tumour
growth suppressive effects in vitro and in vivo, and these agents
act by opening up chromatin thus promoting gene expression,
and also by effects on non-histone proteins, including transcription
factors, transcription co-regulators, signalling mediators and DNA
repair enzymes (reviewed in [6]). High levels of HDACs have been
found in bladder tumours, so HDACi’s may be useful in this disease.
SAHA and MS275 were well tolerated in phase I studies in bladder
cancer [6]. Whilst trichostatin A and belinostat inhibit the growth
of bladder cancer cells in nanomolar and micromolar concentra-
tions, respectively [7,8], we are not aware of similar studies using
panobinostat (PAN), a potent HDACi.
Several HDACi’s radiosensitise a range of tumour cell types and
variously downregulate MRN complex or core NHEJ or HR proteins
in tumour but not normal cells, whilst compromising DNA repair
post-ionising radiation (reviewed in [9]). In addition, HDAC
430 HDAC inhibition in bladder cancerinhibitors have shown no evidence of toxicity in normal cells and
the HDACi H6CAHA even caused an increase in post-irradiation
surviving fraction in normal prostate cells [10–12]. Their potential
clinical use as radiosensitisers has been reported in anaplastic thy-
roid carcinoma, glioma, and gastrointestinal carcinoma (reviewed
in [9]). However, to date there are no published clinical trials of
radiotherapy combined with an HDACi in bladder cancer.
Muscle-invasive bladder tumours have defective NHEJ repair
[13,14], so HDACi’s would be particularly useful if they targeted
the HR pathway, resulting in ‘synthetic lethality’, and hence an in-
creased therapeutic ratio, in combination with IR [15].
We therefore investigated PAN as a potential radiosensitiser in
muscle-invasive bladder cancer. PAN radiosensitised RT112 blad-
der cancer cells and stably-transfected Ku80 knockdown cells,
and appeared to act through the HR pathway, and increased cH2AX
foci formation and delayed resolution after ionising radiation.
Materials and methods
Reagents
Panobinostat (LBH589; PAN) was purchased from Selleck
Chemicals and dissolved in dimethyl sulfoxide (DMSO; Sigma) to
a stock concentration of 1 mmol/L. Single-use aliquots were stored
at 80 C.
Cell culture conditions
TP53 wild-type RT112 bladder transitional cell carcinoma cells
were grown in RPMI-1640 (Sigma) supplemented with 10% v/v foe-
tal bovine serum (FBS; Sigma), 2 mmol/L L-glutamine (Sigma). Sta-
bly transfected knock-down (KD) 795J (RAD51KD), C13 (Ku80KD)
and pSil8 (non-silencing control (NSC)) cells were created from
RT112 cells as previously described [15], and cultured in RPMI-
1640 medium, 10% v/v FBS, 2 mmol/L L-glutamine (Sigma),
0.04 lg/ml G-418 solution (Roche). All cell lines were grown in a
humidiﬁed atmosphere containing 5% CO2 at 37 C and exponen-
tially growing cells were used in all experiments.Chemosensitivity clonogenic assay
Cells were plated at 700–1000 cells per plate in 10 cm dishes
(Greiner Bio-One) for 24 h at appropriate drug concentrations.
The next day plates were washed twice with RPMI-1640 medium
and 10 ml of fresh medium was added to each plate. Fourteen days
later each plate was stained with 0.25% Brilliant blue R (Sigma–Al-
drich): 40% methanol: 7% acetic acid for 30 min. Colonies contain-
ing more than 50 cells were counted automatically using a
Colcounter (Oxford Optronix).Radiosensitisation clonogenic assay
Cells (7.5  105) were plated in 10 cm dishes, and the following
day, treated either with DMSO or PAN at appropriate concentra-
tions. After a further 24 h incubation, cells were trypsinised and
appropriate numbers plated in 10 cm dishes and irradiated at a
dose-rate of 1.7 Gy/min using a caesium-137 source (GSR D1, Gam-
ma-Service Medical GmbH). Cells were then incubated at 37 C for
14 days, before staining and counting as above. The surviving frac-
tion and radiation survival curves were determined and plotted in
GraphPad Prism using the linear-quadratic model as previously
described [15].Western blotting
Western blotting was performed as previously described [15],
using the following antibodies: mouse monoclonal anti-Ku80(Neomarkers), anti-Ku70 (Abcam), anti-Mre11 (Abcam), anti-
H3K18 (Cell Signalling) and anti-b-actin (Abcam), and rabbit
monoclonal anti-NBS1 (Abcam) and anti-RAD51 (Proteintech
Europe).Cell cycle ﬂuorescence-activated cell sorting (FACS) analysis
Cell-cycle analysis was performed as previously described [15].Immunoﬂuorescence
Cells (2.5  105 per dish) were plated onto sterile glass cover-
slips, and the following day treated with PAN or DMSO. Twenty-
four hours later cells were either ﬁxed or irradiated to 5 Gy prior
to ﬁxation, at the time points indicated. Cells were ﬁxed by incuba-
tion for 20 min in 4% paraformaldehyde (Thermo Scientiﬁc)/0.1%
Triton X-100 (Sigma) at room temperature, followed by three PBS
rinses, incubation in 0.5% Triton/PBS for 15 min, then three further
PBS rinses. Coverslips were then blocked for 30 min at room tem-
perature in 5% bovine serum albumin (VWR International Ltd.) be-
fore incubation in mouse monoclonal anti-cH2AX antibody
(Millipore) overnight at 4 C. Following three PBS washes,
coverslips were incubated in secondary anti-rabbit (Alexa 488,
Invitrogen) and anti-mouse (Alexa 568, Invitrogen) antibodies for
1 h before rinsing in PBS three times. Coverslips were mounted
onto slides with Fluoromount G (Sigma) containing 0.1 lg/ml DAPI
(Sigma), dried and scanned on a confocal microscope (Zeiss LSM
780).Statistical analysis
All statistical analyses were conducted using GraphPad Prism
software. Clonogenic assays were performed in duplicate at least
three times, with the results expressed as mean and standard devi-
ation (SD). The sensitiser enhancement ratio (SER) was calculated
at the 0.1 survival fraction (10% survival). In the immunoﬂuores-
cence experiments, slides were prepared twice for each condition
and at least 70 cells counted per slide.
Results
Panobinostat kills bladder cancer cells in the nanomolar range, causes
G2/M cell cycle arrest, and causes cH2AX foci increase
First, we determined the inhibitory effect of panobinostat (PAN)
on growth of RT112, RAD51KD, Ku80KD and NSC cells by clono-
genic assay. After 24 h treatment, IC50 values for PAN were
27 nM in RT112, 25 nM in RAD51KD, 19 nM in Ku80KD and
27 nM in NSC cells; it was therefore more toxic in Ku knockdown
cells (Fig. 1A and Supplementary Fig. 1A).
We also studied PAN’s effect on cH2AX foci formation in RT112
cells (Fig. 1B and Supplementary Fig. 2). We detected a signiﬁcant
increase in the number of cH2AX foci per cell (P = 0.022 at 25 nm
and P = 0.002 at 50 nM).
We then tested the effects of increasing concentrations of PAN
on cell cycle progression (Fig. 1C and Supplementary Fig. 3). PAN
caused G2/M phase arrest in a concentration-dependent manner
(statistically signiﬁcant at 25, 50 and 100 nM PAN, P = 0.01,
P = 0.02 and P = 0.02, respectively).Panobinostat downregulates MRE11, NBS1 and RAD51 proteins
Next, we determined the effects of PAN on key DNA damage sig-
nalling and repair proteins by western blotting. PAN downregu-
lated protein levels of MRE11 and NBS1 in a dose-dependent
manner (Fig. 1D). RAD51 was also downregulated, but PAN did
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Fig. 1. (a) Clonogenic assays following 24 h treatment of RT112, RAD51KD and Ku80KD cells with increasing PAN concentrations. All experiments were performed at least
three times. Error bars represent the mean and standard deviation (SD). (b) Quantiﬁcation of cH2AX foci in DMSO- or PAN-treated cells, 24 h after treatment (see
Supplementary Fig. 2 for confocal images). (c) Cell-cycle phase distributions in cells treated with increasing concentrations of PAN for 24 h. (d) Western blots from RT112 cells
incubated with PAN for 24 h, showing downregulation of MRE11, NBS1 and RAD51 but not Ku70 or Ku80, with acetylation of H3K18 from 10 nM or greater PAN.
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ﬁrmed PAN’s action at 10 nM and above.Panobinostat radiosensitises bladder cancer cells, particularly
Ku-deﬁcient
Cells were treated at 10 nM and 25 nM PAN concentrations,
approximately equivalent to RT112’s IC10 and IC40. PAN signiﬁ-
cantly sensitised Ku80KD cells at 10 nM (SER = 1.35, P = 0.04) with
less marked effects in parental RT112 cells (SER = 1.16, P = 0.05)
and RAD51KD cells (SER = 1.22, P = 0.04). At 25 nM PAN (IC40),
the SER for both RT112 and RAD51KD cells was 1.31 (P = 0.01
and P = 0.03, respectively), but this was higher for Ku80KD cells
at a Ku80KD IC20 equivalent dose (1.56, P = 0.05; Fig. 2A and B).Panobinostat delays cH2AX foci resolution after 5 Gy irradiation
We examined cH2AX foci resolution at 4, 24 and 48 h post 5 Gy
irradiation in PAN and DMSO treated samples (Fig. 2C and D). We
detected a signiﬁcant delay in cH2AX foci resolution in PAN trea-
ted samples at 24 and 48 h time points (P = 0.003 and P = 0.03,
respectively).Effects of panobinostat on RAD51 and Ku70/Ku80
RAD51, Ku70/80 and histone H3K18 expression were measured
by Western blot after 25 nM PAN ± 5 Gy (Fig. 3). RAD51 and Ku80
levels were reduced as expected in the respective knockdown cells.
PAN reduced RAD51 levels in all cell lines and attenuated the
RAD51 upregulation seen after 5 Gy. Ku70 and Ku80 protein levels
were not markedly affected by PAN treatment.Discussion
To our knowledge, this is the ﬁrst reported study using PAN in
bladder cancer cell lines and the ﬁrst to show its radiosensitising
effects in bladder cancer.
We found PAN to have potent cytotoxic effects in the RT112
bladder cancer cell line and its Ku80 and RAD51 stably transfected
knockdown counterparts, with downregulation of RAD51, MRE11
and NBS1 but not Ku70 or Ku80 in RT112 cells. Strikingly, PAN
was more toxic in the Ku80KD cell line than RT112 or RAD51KD
cells. We tested PAN’s effects on cell cycle progression in RT112
cells and, at doses of 25 nM and above, found a signiﬁcant accumu-
lation of cells in G2/M phase, where HR is the predominant DSB
repair mechanism, but this was not seen at 10 nM.
Our RAD51 KD cell lines showed a similar radiosensitivity pro-
ﬁle by clonogenic assay to the parental RT112 cell line, whilst the
Ku80 KD cell line was more radiosensitive, with surviving fractions
after 6 Gy of IR of 27%, 28% and 18%, respectively. HR appears to be
less important than NHEJ for repairing IR-induced breaks in higher
eukaryotes, especially in G1 phase, although HR contributes in the
late S/G2 phase [16]. We found PAN to be an efﬁcient radiosensitis-
er in the RT112 bladder cancer cells used in this report and also
two other high grade bladder cancer cell lines (Supplementary
Fig. 1). Here, PAN was a particularly efﬁcient radiosensitiser in
Ku80KD cells. PAN had an equal efﬁcacy at Ku80KD IC20 (10 nM)
and RT112 IC40 levels (25 nM), with SERs of 1.35 and 1.31, respec-
tively. These data suggest that PAN’s greater radiosensitising effect
in KuKD cells is not due solely to the increased toxicity of the drug
in these cells. Neither is it likely to be due to cell cycle effects at the
lower doses (data not shown). Our results were similar to those we
previously found for the tyrosine kinase inhibitor imatinib, which
targets RAD51 [15]. However, our PAN results were more striking
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Fig. 2. (a) Clonogenic assays in RT112, RAD51KD and Ku80KD cells treated with increasing ionising radiation doses and 10 nM or 25 nM PAN; (b) Percentages of cells
surviving after 6 Gy, quantiﬁed from (a); (c) quantiﬁcation of cH2AX foci from (d); (d) Confocal images of cH2AX foci (top panels) and DAPI stained cells (bottom panels) for
cells treated with and without 5 Gy IR and 25 nM PAN.
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PAN on MRE11 and NBS1. Downregulation of the MRN complex
by siRNA or NBS1 or MRE11 mutation is known to result in radio-
sensitisation [17,18] and the additional impact of PAN on these
proteins higher in the DNA damage signalling pathway may ac-
count for our ﬁndings.
We measured cH2AX as a marker of DNA damage and repair
and found that PAN upregulated the number of cH2AX foci seen
at 24 h. Studies using other HDACi’s also show similar effects
[19]. When cells were irradiated with 5 Gy after incubation with
25 nM PAN, we detected a signiﬁcant delay in cH2AX foci resolu-
tion, indicating supressed repair of DNA DSB in PAN treated cells.
Geng et al. [20] showed similar effects for PAN with 3 Gy irradia-
tion in lung cancer cells. We are, however, aware of the limitationsof the cH2AX assay as a measure of DSB repair, particularly in non-
G0/G1 cells, since cH2AX formation can occur at single-stranded
DNA regions during replication or repair [21]. Also background,
endogenous ‘cryptogenic’ foci can limit the ability to detect resid-
ual IR-induced cH2AX foci [22].
In using only the cH2AX assay to measure DNA damage and re-
pair, we have not comprehensively examined the effects of PAN on
the NHEJ and HR pathways. To do this requires assays such as the
NHEJ assay suitable for use on small scale extracts from cell lines
[23] and the widely reported HR I-SceI-based reporter assay [24].
We have found previously that Ku80 expression by western blot
and immunohistochemistry is variable and does not correlate with
bladder cancer grade and stage [13]. However, muscle-invasive
bladder tumours display reduced Ku-DNA binding (as previously
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Fig. 3. Western blot analyses of RT112, RAD51KD and Ku80KD cells. Cells were incubated with or without 25 nM PAN for 24 h, and then harvested and irradiated to 5 Gy or
left untreated. Cells were lysed 4 h later. Experiments were performed at least twice.
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defective. Therefore agents targeting the HR pathway could result
in ‘synthetic lethality’, whereby normal cells, with intact NHEJ,
can still repair IR-induced DNA damage via NHEJ despite HR being
targeted, whilst tumour cells defective in NHEJ are less able to
repair the damage. In terms of biomarker development for the pre-
diction of response to panobinostat, it would be interesting to test
whether low Ku-expressing tumours respond better to panobino-
stat, although the reduced Ku-DNA binding phenotype may over-
ride this effect.
Whilst others have variously shown effects of HDACi’s on the
MRN complex, RAD51 and Ku70/80, we believe we are the ﬁrst
to study all three aspects together [9]. PAN is a potent HDACi
and the plasma levels used in this study can be reached safely in
patients [26]. PAN is therefore a promising agent for investigation
as an efﬁcient future therapy in combination with radiation in
bladder cancer.Conﬂicts of interest
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